JCR Pharmaceuticals Co., Ltd. (JCRRF)
- Previous Close
5.22 - Open
5.22 - Bid --
- Ask --
- Day's Range
5.22 - 5.22 - 52 Week Range
5.22 - 10.76 - Volume
100 - Avg. Volume
1 - Market Cap (intraday)
655.616M - Beta (5Y Monthly) -0.01
- PE Ratio (TTM)
18.64 - EPS (TTM)
0.28 - Earnings Date --
- Forward Dividend & Yield 0.13 (2.53%)
- Ex-Dividend Date Mar 28, 2024
- 1y Target Est
--
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
www.jcrpharm.co.jp879
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: JCRRF
Performance Overview: JCRRF
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JCRRF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JCRRF
Valuation Measures
Market Cap
655.34M
Enterprise Value
687.63M
Trailing P/E
18.90
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.45
Price/Book (mrq)
1.81
Enterprise Value/Revenue
0.02
Enterprise Value/EBITDA
0.09
Financial Highlights
Profitability and Income Statement
Profit Margin
12.97%
Return on Assets (ttm)
5.03%
Return on Equity (ttm)
9.93%
Revenue (ttm)
41.37B
Net Income Avi to Common (ttm)
5.36B
Diluted EPS (ttm)
0.28
Balance Sheet and Cash Flow
Total Cash (mrq)
18.3B
Total Debt/Equity (mrq)
41.65%
Levered Free Cash Flow (ttm)
--
Company Insights: JCRRF
JCRRF does not have Company Insights